Physician profile
Agnes M Laus
NPI 1881670974
$1,386.61
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2020: $125 · 2021: $264 · 2022: $108 · 2023: $436 · 2024: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $650.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $169.97 | 2022-2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $141.84 | 2019-2023 | Trintellix |
| Abbott Laboratories | $106.40 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $98.09 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $94.28 | 2019-2023 | Vaxelis, M-M-R II, Gardasil 9 |
| Amarin Pharma, INC. | $76.03 | 2019-2021 | |
| Novo Nordisk INC | $69.02 | 2019-2023 | Wegovy |
| Pfizer INC. | $57.84 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $49.76 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $47.72 | 2019-2024 | Arexvy, Shingrix, Bexsero |
| Exact Sciences Corporation | $47.22 | 2023 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $46.34 | 2022-2024 | |
| Cranial Technologies, INC | $42.41 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $39.94 | 2020-2023 | Breztri |
| Sanofi Pasteur INC. | $33.44 | 2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $31.72 | 2023-2024 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.84 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $27.20 | 2019-2020 | |
| Genentech USA, INC. | $25.99 | 2020 | |
| Medtronic, INC. | $23.54 | 2023 | Linq II |
| Phathom Pharmaceuticals, INC. | $20.60 | 2024 | Voquezna |
| Lucid Diagnostics INC. | $19.67 | 2024 | |
| Xeris Pharmaceuticals, INC. | $14.43 | 2023 | Gvoke Hypopen |
| Ironshore Pharmaceuticals INC. | $13.88 | 2019 | |
| Amgen INC. | $13.68 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.53 | 2019 | |
| Smith+Nephew, INC. | $12.07 | 2019 | |
| Alfasigma USA, INC. | $11.35 | 2021 | |
| Arbor Pharmaceuticals, INC. | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Agnes Laus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.